PHAT Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -250.98% compared to Phathom Pharmaceuticals's net margin of -49.65%. Phathom Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Phathom Pharmaceuticals has a consensus price target of $21.13, signalling upside risk potential of 284.79%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 48.6%. Given that Phathom Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Phathom Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Phathom Pharmaceuticals has a beta of 0.351, which suggesting that the stock is 64.87% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals quarterly revenues are $29.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Phathom Pharmaceuticals's net income of -$74.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 6.28x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -250.98% compared to Phathom Pharmaceuticals's net margin of -2357.27%. Phathom Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Phathom Pharmaceuticals has a consensus price target of $21.13, signalling upside risk potential of 284.79%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1200.63%. Given that Palatin Technologies has higher upside potential than Phathom Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Phathom Pharmaceuticals.

Phathom Pharmaceuticals has a beta of 0.351, which suggesting that the stock is 64.87% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals quarterly revenues are $29.7M, which are larger than Palatin Technologies quarterly revenues of $350K. Phathom Pharmaceuticals's net income of -$74.5M is lower than Palatin Technologies's net income of -$2.4M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 6.28x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of -250.98% compared to Phathom Pharmaceuticals's net margin of 8.48%. Phathom Pharmaceuticals's return on equity of -- beat Stryker's return on equity of 15.22%.

Phathom Pharmaceuticals has a consensus price target of $21.13, signalling upside risk potential of 284.79%. On the other hand Stryker has an analysts' consensus of $423.40 which suggests that it could grow by 12.17%. Given that Phathom Pharmaceuticals has higher upside potential than Stryker, analysts believe Phathom Pharmaceuticals is more attractive than Stryker.

Phathom Pharmaceuticals has a beta of 0.351, which suggesting that the stock is 64.87% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Phathom Pharmaceuticals quarterly revenues are $29.7M, which are smaller than Stryker quarterly revenues of $6.4B. Phathom Pharmaceuticals's net income of -$74.5M is lower than Stryker's net income of $546M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Stryker's PE ratio is 48.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 6.28x versus 6.44x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -250.98% compared to Phathom Pharmaceuticals's net margin of --. Phathom Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Phathom Pharmaceuticals has a consensus price target of $21.13, signalling upside risk potential of 284.79%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 408.48%. Given that Theriva Biologics has higher upside potential than Phathom Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Phathom Pharmaceuticals.

Phathom Pharmaceuticals has a beta of 0.351, which suggesting that the stock is 64.87% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals quarterly revenues are $29.7M, which are larger than Theriva Biologics quarterly revenues of --. Phathom Pharmaceuticals's net income of -$74.5M is lower than Theriva Biologics's net income of -$4.4M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 6.28x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.